Press "Enter" to skip to content

FDA approves first treatment for rare blood disease

The FDA approved Elzonris (tagraxofusp-erzs) infusion for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients, two years of age and older.

Original source:

Also Read:   FDA Authorizes Marketing of Novel Device to Help Protect Athletes’ Brains During Head Impacts